• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Catalent

MedTech 100 roundup: Markets dip again

June 29, 2020 By Sean Whooley

Medtech stocks continue to fluctuate amid the COVID-19 pandemic, with a significant dip in the shares belonging to the industry’s biggest names. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 81.88 points at the end of last week (June 26). That total represents a -3.7% decrease […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Research & Development, Wall Street Beat Tagged With: Artegraft, Catalent, FDA, Henry Schein Inc., LeMaitre Vascular Inc., MedTech 100 Index, Medtech Innovator, Moderna, U.S. Department of Defense

Moderna, Catalent partner on COVID-19 vaccine candidate manufacturing

June 25, 2020 By Nancy Crotti

Moderna (NSDQ:MRNA) and Catalent (NYSE:CTLT) today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Ind. Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million doses […]

Filed Under: Business/Financial News, Contract Manufacturing, Drug-Device Combinations, Featured, Pharmaceutical Tagged With: Catalent, COVID-19, Moderna

Catalent launches $400m public offering

July 23, 2018 By Sarah Faulkner

Catalent (NYSE:CTLT) said today that it launched a $400 million underwritten public offering of its common stock. The Somerset, N.J.-based company plans to give underwriters a 30-day option to buy up to $60 million in additional shares of common stock. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Funding Roundup, Pharmaceutical, Wall Street Beat Tagged With: Catalent

Catalent expands early-phase development skills with $139m Juniper buyout

July 3, 2018 By Sarah Faulkner

Catalent (NYSE:CTLT) said today that it inked a $139 million deal to acquire Juniper Pharmaceuticals (NSDQ:JNPR) and its early-stage product development services. The company noted that its Juniper acquisition, set at $11.50 per share, will complement Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities. Get the full story at our sister site, Drug Delivery […]

Filed Under: Mergers & Acquisitions, Pharmaceutical, Research & Development, Wall Street Beat Tagged With: Catalent

Catalent reorganizes after closing Pharmica purchase

October 24, 2017 By Sarah Faulkner

Cook Group said today that it completed the sale of Cook Pharmica to Catalent (NYSE:CTLT). Catalent announced last month that it planned to dish out $950 million to buy the biologics contract manufacturer. The newly-acquired company will be called Catalent Bloomington, according to Cook Group. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: Catalent, Cook Group Inc., cookpharmica

Catalent launches $450m private offering

October 10, 2017 By Sarah Faulkner

Catalent (NYSE:CTLT) said today that its subsidiary, Catalent Pharma Solutions, plans to offer $450 million in senior unsecured notes due 2026. The private offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Drug-Device Combinations, Funding Roundup, Pharmaceutical, Wall Street Beat Tagged With: Catalent

Catalent prices offering to help fund Cook Pharmica acquisition

September 27, 2017 By Sarah Faulkner

Catalent today priced an underwritten public offering for 6,395,000 shares of its common stock at $39.10 apiece. The offering will be used to fund, in part, the drug-delivery company’s $950 million purchase of biologics manufacturer, Cook Pharmica. In connection with the offering, Catalent granted underwriters a 30-day option to buy up to an additional 959,250 shares of […]

Filed Under: Funding Roundup, Mergers & Acquisitions, Pharmaceutical Tagged With: Catalent, cookpharmica

Catalent floats $250m public offering to fund Cook Pharmica purchase

September 26, 2017 By Sarah Faulkner

Catalent said today that it launched an underwritten public offering for $250 million of its common stock to fund, in part, its $950 million purchase of biologics manufacturer Cook Pharmica. In connection with the offering, Catalent is slated to grant underwriters a 3o-day option to buy up to $37.5 million of additional shares of common stock. Get […]

Filed Under: Contract Manufacturing, Funding Roundup, Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: Catalent, cookpharmica

Catalent dishes out $950m for biologics manufacturer

September 19, 2017 By Sarah Faulkner

Catalent said today that it plans to purchase Cook Pharmica for $950 million in cash. Cook Pharmica, a unit of privately-held medical device maker Cook Group, is a contract manufacturer that develops biologics-based drug compounds. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Contract Manufacturing, Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: Catalent

Catalent, Rutgers partner to study pediatric drug formulation and delivery

July 20, 2017 By Sarah Faulkner

The Catalent Applied Drug Delivery Institute said today that it inked a deal to work with the dept. of pharmacy practice at Rutgers University in an effort to identify and address the challenges linked to pediatric drug formulation and delivery. The collaboration plans to focus on the development and administration of medicines to children by […]

Filed Under: Pharmaceutical, Research & Development, Respiratory Tagged With: Catalent, rutgersuniversity

Nanoparticles: An industry buzzword meets reality

May 31, 2017 By Sarah Faulkner

Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?” It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Boehringer Ingelheim Pharmaceuticals, Catalent, Cerulean Pharma Inc., Dicerna Pharmaceuticals, latonatherapeutics

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS